I farmaci biologici nelle patologie autoimmuni
16 - 17 Maggio 2014, Genova Di.M.I. Sala Conferenze
FARMACI BIOTECNOLOGI: DALLA NORMATIVA DI RIFERIMENTO ALLE NUOVE PROSPETTIVE

Farmaci biosimilari: l'esperienza del farmacista

Federico Ferro

REGIONE LIGURIA
AZIENDA SANITARIA LOCALE N. 4
"Chiavarese"


€ 300.000,00
€ 250.000,00
€ 200.000,00
€ 150.000,00
€ 100.000,00
€ 50.000,00
€ -
2012
2013
Farmaci
Fattori di crescita eritropoietici



Andamento spesa per fattori di crescita eritropoietici

(valori espressi in euro)


5000000
4000000
3000000
2000000
1000000
0
-1000000
12_01
12_02
12_03
12_04
12_05
12_06
12_07
12_08
12_09
12_10
12_11
12_12
13_01
13_02
13_03
13_04
13_05
13_06
13_07
13_08
13_09
13_10
13_11
13_12
DARBEPOETINA ALFA
EPO ALFA
EPO ALFA BIOS
EPO BETA
Totale complessivo



PERCENTUALE BIOSIMILARI RISPETTO AL TOTALE DELLA SPESA PER I FATTORI DI CRESCITA ERITROPOIETICI



Source IMS MIDAS



Percentuale spesa biosimilari ASL4